We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Belgian biotech's clot-buster approved for aging eyes.
- Authors
Sheridan, Cormac
- Abstract
The article presents information on a recombinant protein drug "Jetrea," developed by ThromboGenics NV that has received the approval from the U.S. Food and Drug Administration (FDA) for the treatment of the vitreous macular adhesion (VMA). It informs that the company is also on the verge of receiving an opinion from the European Medicines Agency's Committee on Human Medicinal Products (CHMP).
- Subjects
RECOMBINANT proteins; DRUG development; THROMBOGENICS NV; UNITED States. Food &; Drug Administration; ADHESION; EUROPEAN Medicines Agency
- Publication
Nature Biotechnology, 2012, Vol 30, Issue 12, p1158
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt1212-1158b